Home Page
18:15:21 EDT Sat 01 Aug 2015
Enter Symbol
or Name
USA
CA



Z:SNY - SANOFI - http://www.sanofi-aventis.com18:15:21 EDT
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SNY - Z1.052.81 · 58.000.253.99+0.420.8862.041,5205,12653.88  54.25  53.6457.42  43.5717:16:52Jul 3015 min RT 2¢

Recent Trades - Last 10 of 5126
Time ETExPriceChangeVolume
17:16:52Z53.940.374,038
16:29:46Z53.990.42720
16:04:04Z53.990.42200
16:03:47Z53.990.4240,829
15:59:58Z53.9350.365100
15:59:55Z53.9250.355100
15:59:55Z53.9250.35512
15:59:48Z53.9250.35522
15:59:47Z53.9250.355100
15:59:44Z53.920.3579
Recent Bulletins
Date ETSymbolTypeHeadline
2015-07-30 07:30SNYNews ReleaseSanofi Delivers Solid Sales and Business EPS Growth in Q2 2015
2015-07-30 02:45SNYNews ReleaseSanofi H1 2015 Results - Interview with CEO Olivier Brandicourt
2015-07-29 08:00SNYNews ReleaseGenzyme Launches Fifth Annual Patient Advocacy Leadership (PAL) Awards Program
2015-07-29 07:00SNYNews ReleaseSanofi Announces that First LixiLan Phase III Study Met Primary Endpoint
2015-07-28 01:00SNYNews ReleaseRegeneron and Sanofi Launch Major New Immuno-Oncology Collaboration
2015-07-27 02:00SNYNews ReleaseGenzyme Strengthens Endocrinology Portfolio with Acquisition of Rare Disease Therapy Caprelsa ® (vandetanib) from AstraZeneca
2015-07-24 15:53SNYNews ReleaseSanofi and Regeneron Announce FDA Approval of Praluent ® (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., for the Treatment of High LDL Cholesterol in Adult Patients
2015-07-24 15:17SNYNews ReleaseRegeneron and Sanofi Announce FDA Approval of Praluent ® (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., for the Treatment of High LDL Cholesterol in Adult Patients
2015-07-24 07:15SNYNews ReleaseRegeneron and Sanofi Announce CHMP Recommends European Approval of Praluent ® (alirocumab) for the Treatment of Hypercholesterolemia
2015-07-14 08:00SNYNews ReleaseSanofi Pasteur Ships First 2015-2016 Seasonal Influenza Vaccine Doses in United States
2015-07-10 09:28SNYNews ReleaseMerial Introduces Oravet ® Dental Hygiene Chews for Dogs
2015-07-08 22:00SNYNews ReleaseRegeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent ® (alirocumab) Injection